Eli Lilly raises full-year revenue outlook on weight-loss drug sales, trims profit view on deal charges
Lilly's Q3 beat and higher guidance reinforced its dominant position in the obesity market, though acquisition charges and a looming triple-agonist race keep in
pharma.economictimes.indiatimes.com · +8 outlets
Hengrui Pharma signs deal worth up to $2.6B with Novo Nordisk for oral GLP-1 drug
The licensing pact signals Novo's push to bolster its oral obesity pipeline as competition with Lilly's injectables intensifies.
scanx.trade · +6 outlets
Indian regulator slashes cancer drug prices by up to 89% across 543 brands effective Nov 9
The NPPA's new ceiling prices and a 30% trade margin cap aim to curb mark-ups but leave many patients facing continued affordability gaps.
Pragativadi · +7 outlets
INOVIO wins FDA accelerated approval for VOCERYQ
The accelerated nod marks a regulatory milestone for INOVIO's DNA-medicine platform.
Stock Titan · +9 outlets
India orders Sun Pharma to halt eye-care drug production at Assam plant after quality lapses
The manufacturing halt raises fresh compliance questions for Sun Pharma's US-linked supply chain.
The Hindu · +11 outlets
US drugmakers raise outlooks on record revenue despite Trump pricing pressure
Big pharma's strong guidance shows pricing pressure from Washington has not yet dented top-line growth.
MedWatch · +6 outlets
Regeneron surges 12% on Dupixent windfall and Eylea HD earnings beat
Regeneron's beat highlighted strength in its Sanofi-partnered immunology franchise despite Moderna weakness.
24/7 Wall St. · +2 outlets
Biomarin strikes deal worth up to $475M with GC Biopharma, Hanmi for Fabry disease drug
The Korean partnership expands BioMarin's rare disease footprint amid pricing pressure in the segment.
KED Global · +3 outlets
Agios sickle cell drug FDA review extended to Feb. 1, 2027
The three-month delay pushes a key catalyst for Agios' hematology portfolio into 2027.
Stock Titan · +7 outlets
FDA approves Ilumya for adults with active psoriatic arthritis
The label expansion broadens Sun Pharma's immunology drug into a new inflammatory indication.
Pharmaceutical Executive · +13 outlets
Alnylam CEO says 'we need to do better' as uncertainty looms over transthyretin franchise
Leadership's admission comes amid competitive and clinical pressure on Alnylam's key amyloidosis business.
BioSpace · +1 outlets
Vertex Pharmaceuticals faces key FDA test after RAINIER data
Investors see the upcoming regulatory decision as pivotal for Vertex's pipeline beyond cystic fibrosis.
ad-hoc-news.de · +1 outlets
Alzheimer's drug misses main trial goal; developer plans to stop development
The late-stage failure is a setback for the Alzheimer's pipeline amid intense CNS drug development interest.
Stock Titan · +1 outlets
Novo Nordisk earnings preview: what to watch in obesity drug franchise
Investors focus on whether obesity data and guidance can steady Novo's investment narrative.
Morningstar · +9 outlets
Pfizer, AbbVie win FDA nod among week's biopharma approvals and deals
The weekly roundup shows continued FDA activity alongside job cuts and licensing deals across the sector.
RTTNews · +1 outlets
Keytruda biosimilars are coming but face an uphill commercial battle
The looming patent cliff on Merck's top-selling cancer drug opens the door for biosimilar competition.
Pharma Voice · +1 outlets
Hunter syndrome's first new FDA-approved treatment in nearly 20 years wins 2026 award
The recognition highlights a rare-disease therapy breakthrough after two decades without new options.
Stock Titan
PhRMA challenges CMS GLOBE model in new Medicare Part B drug pricing fight
The litigation reflects the deepening battle over Medicare drug price negotiations.
RamaOnHealthcare · +1 outlets